User:Mr. Ibrahem/Insulin degludec

Insulin degludec, under the brand name Tresiba is an long-acting insulin used to treat type I and type II diabetes. It once daily by injection under the skin. Onset of effects occur within 90 minutes and last for more than 42 hours. After a few days it has a steady effects at all hours.

Common side effects include low blood sugar, allergic reactions, pain at the site of injection, itchiness, rash, weight gain, and lipodystrophy. It has a lower risk of low blood sugar compared to long acting detemir and glargine. Other side effects may include low potassium. In pregnancy NPH insulin is preferred. It is a form of insulin made by recombinant DNA technology and than further modified.

Insulin degludec was approved for medical use in Europe in 2013 and the United States in 2015. It is on the World Health Organization's List of Essential Medicines. In the United Kingdom a 300 unit pen costs the NHS about £9 as of 2021. In the United States this amount costs about 100 USD. In 2019, it was the 168th most commonly prescribed medication in the United States, with more than 3 million prescriptions. It is also available in combination with liraglutide.